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Introduction
Childhood obesity has become an increasingly 
prevalent problem in the United States, with 
the rate of obesity in children and adolescents 
increasing from 6.1% in the 1972–1974 
National Health and Nutrition Examination 
Survey I (NHANES I) to 18.1% in NHANES 
2007–2008 (Ogden and Carroll 2010). The 
causes associated with this accelerating rate are 
being investigated, and an emerging hypothesis 
is that exposure to ubiquitous environmental 
toxicants may play a role in these childhood 
growth patterns (reviewed by Newbold 2010). 
Polycyclic aromatic hydrocarbons (PAHs) are 
a family of chemicals that are created through 
the incomplete combustion of organic materi-
als [Agency for Toxic Substances and Disease 
Registry (ATSDR) 1995, 2005]. They are 
pervasive in our environment and distributed 
widely in the atmosphere. Nearly 100% of 
urinary samples collected through NHANES 
contain metabolites of naphthalene, fluorene, 
phenanthrene, and pyrene (Huang et al. 2006; 
Li et al. 2008). Humans can be exposed to 
PAHs through inhalation of cigarette smoke, 
vehicle exhaust, and processed fossil fuels, or 
through ingestion of grilled and charred meats, 
contaminated flour and bread products, pro-
cessed and pickled foods, and contaminated 
water and cow’s milk (ATSDR 1995, 2005). 
Contact with air, water, or soil near hazardous 
waste sites also poses a threat for exposure; 
nursing infants whose mothers live near these 
sites are an especially susceptible population to 
exposure through their mothers’ milk. PAHs 
consist of two or more fused aromatic rings. 
Low-molecular-weight PAHs that have two or 
three aromatic rings are emitted in the gaseous 
phase, whereas high-molecular-weight PAHs, 
with five or more rings, are emitted in the par-
ticulate phase (ATSDR 1995, 2005).
PAHs are known carcinogens and sus-
pected endocrine disruptors. Hydroxylated 
PAHs, the main metabolic product of PAHs, 
are structurally similar to estrogen and have 
been shown to have estrogenic activities 
(Schultz and Sinks 2002; Wenger et al. 2009). 
There is evidence that PAHs may act either 
antiestrogenically or estrogenically through dis-
rupting estrogen-mediated pathways (Gozgit 
et al. 2004; Sievers et al. 2013). Some PAHs, 
such as phenanthrene and to a lesser extent 
fluoranthene, show antiandrogenic effects 
(Chang and Liao 1987; Vinggaard et al. 2000). 
Sun et al. (2008) showed that 1-naphthol 
and 2-naphthol may act as thyroid hormone 
receptor antagonists. Additionally, PAHs 
are transported into all tissues of the human 
body containing fat and have strong lipophilic 
properties. They can be stored in fat cells, the 
liver, and the kidneys and can accumulate by 
repeated and long-term exposures (Laher et al. 
1984; Shu and Nichols 1979). Furthermore, 
experiments done in mice have shown that 
benzo[a]pyrene, a high-molecular-weight PAH, 
impairs adipose tissue lipolysis and leads to 
increased weight gain, increased fat mass, and 
changes in food intake (Irigaray et al. 2006).
Recently, studies have shown that prenatal 
exposure to PAHs is associated with reduced 
birth weight and birth head circumference as 
well as smaller birth size for gestational age 
among African Americans (Choi et al. 2008; 
Perera et al. 2003). Moreover, a study done in 
New York City (USA) showed a positive asso-
ciation between maternal exposure to PAHs 
during pregnancy and increased rates of obe-
sity in early childhood (Rundle et al. 2012). 
The objective of our study was to investigate 
whether low-molecular-weight PAHs are asso-
ciated with adiposity outcomes [body mass 
index (BMI) z-score and rate of obesity] in 
children and adolescents (6–19 years of age) 
using data from NHANES 2001–2006.
Methods
Study population. The NHANES studies 
from 2001–2006 were conducted by the U.S. 
National Center for Health Statistics [NCHS; 
Centers for Disease Control and Prevention 
(CDC), Atlanta, GA] with biomonitoring 
data evaluated by the National Center for 
Environmental Health (NCEH). The stud-
ies are cross-sectional, multistage, nationally 
representative surveys of the noninstitutional-
ized civilian population of the United States 
(NCHS 2008a). NCHS maintains that insti-
tutional review board approval and informed 
Address correspondence to F. Scinicariello, Centers 
for Disease Control and Prevention, Agency for Toxic 
Substances and Disease Registry, 4770 Buford Hwy., 
MS F57, Atlanta, GA 30341 USA. Telephone: (770)-
488-3331. E-mail: fes6@cdc.gov
Supplemental Material is available online (http://
dx.doi.org/10.1289/ehp.1307234).
This research was supported in part by an appoint-
ment to the Research Participation Program at the 
Centers for Disease Control and Prevention (CDC) 
administered by the Oak Ridge Institute for Science 
and Education through an interagency agreement 
between the U.S. Department of Energy and CDC 
(M.C.B.).
The findings and conclusion in this report are 
those of the authors and do not necessarily represent 
the views of CDC/Agency for Toxic Substances and 
Disease Registry.
The authors declare they have no actual or potential 
competing financial interests.
Received: 17 June 2013; Accepted: 24 December 
2013; Advance Publication: 3 January 2014; Final 
Publication: 1 March 2014.
Urinary Polycyclic Aromatic Hydrocarbons and Childhood Obesity: NHANES 
(2001–2006)
Franco Scinicariello and Melanie C. Buser
Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry (ATSDR), Atlanta, Georgia, USA
Background: Polycyclic aromatic hydrocarbons (PAHs) are known carcinogens and 
 suspected endocrine disruptors. Prenatal exposure to PAHs has been associated with obesity in 
early childhood.
oBjective: We examined the association of urinary PAH metabolites with adiposity outcomes 
[body mass index (BMI) z-score, waist circumference (WC), and rate of obesity] in children and 
adolescents.
Methods: We performed whole-sample analyses of 3,189 individuals 6–19 years of age who par-
ticipated in the 2001–2006 National Health and Nutrition Examination Survey. We performed 
multivariate linear and logistic regression to analyze the association of BMI z-score, WC, and obe-
sity with concentrations of single urinary PAH compounds and the sum of PAHs. Furthermore, 
the analyses were stratified by developmental stage [i.e., children (6–11 years) and adolescents 
(12–19 years)].
results: BMI z-score, WC, and obesity were positively associated with the molecular mass sum of 
the PAHs and the total sum of naphthalene metabolites. Most associations increased monotonically 
with increasing quartiles of exposure among children 6–11 years of age, whereas dose–response 
trends were less consistent for adolescents (12–19 years of age). Neither total PAHs nor total 
naphthalene metabolites were associated with overweight in either age group, and there was little 
evidence of associations between the outcomes and individual PAHs.
conclusions: Total urinary PAH metabolites and naphthalene metabolites were associated with 
higher BMI, WC, and obesity in children 6–11 years of age, with positive but less consistent asso-
ciations among adolescents.
citation: Scinicariello F, Buser MC. 2014. Urinary polycyclic aromatic hydrocarbons and child-
hood obesity: NHANES (2001–2006). Environ Health Perspect 122:299–303; http://dx.doi.
org/10.1289/ehp.1307234
Scinicariello and Buser
300 volume 122 | number 3 | March 2014 • Environmental Health Perspectives
consent was obtained from all participants in 
these surveys. The grouping we used consisted 
of three cycles (2001–2002, 2003–2004, 
and 2005–2006) that were combined using 
NCHS recommendations (NCHS 2008b). 
Interviews were conducted in participants’ 
homes and extensive physical examinations, 
which included blood and urine collection, 
were conducted at mobile examination centers. 
Measure of adiposity: BMI z-score, waist 
circumference, and obesity. BMI is calculated 
by the weight divided by height squared (kilo-
grams per meter squared). However, because 
the relation between BMI and body weight 
in children depends on age and sex, it is more 
appropriate to calculate the BMI z-score. The 
BMI z-score is the number of standard devia-
tions (SDs) by which a child differs from the 
mean BMI of children of the same age and sex. 
Thus, the BMI z-score allows comparison of 
children of different ages and both sexes. The 
age and sex independent BMI z-scores were 
calculated using the methodology provided by 
the CDC (2011). 
Individuals were classified as overweight 
and obese by BMI z-score between the 85th 
and 94th percentile and ≥ 95th percentile, 
respectively, for age and sex. Waist circum-
ference (WC) was measured by trained 
technicians to the nearest 0.1 cm using 
 standardized protocol.
Covariates. We controlled for the follow-
ing a priori confounders of the association 
between PAHs and BMI z-score and obesity: 
age, race/ethnicity, sex, urinary creatinine, 
poverty:income ratio (PIR), serum cotinine, 
serum C-reactive protein (CRP), calorie intake, 
and television, video game, and computer use. 
PIR is a measure of socioeconomic status and 
represents the calculated ratio of household 
income to the poverty threshold after account-
ing for inflation and family size.
Caloric intake was categorized as “normal” 
and “excessive” based on the U.S. Department 
of Agriculture (2010) calorie intake guidelines 
by age and sex. The individual cut-off caloric 
need was the highest value for the range by age 
and sex assuming a moderate physical activity 
level. Information on daily hours of television, 
video game, or computer use was obtained by 
questionnaire, and the covariate was categorized 
with a cut point of ≥ 2 hr/day.
Laboratory analysis. PAH metabolites 
were measured in spot urine samples obtained 
from a random subsample of one-third of sub-
jects ≥ 6 years of age. The eight monohydroxy-
PAHs (OH-PAHs) we investigated were 
measured using gas chromatography com-
bined with high-resolution mass spectrom-
etry, as detailed by Romanoff et al. (2006). 
Additionally, we created three other variables: 
the sum of the individually calculated molar 
mass of all PAH metabolites (∑molPAHs), 
the sum of the naphthalene metabolites 
(∑NAPHT), and the sum of the metabo-
lites of the PAHs with three (fluorene and 
phenanthrene) or four (pyrene) benzene rings 
(∑mol3–4PAHs). To account for variation 
in dilution in spot urinary samples, urinary 
creatinine was entered in the analyses as an 
independent variable, as suggested by previous 
studies (Barr et al. 2005; Ikeda et al. 2003). 
Urinary creatinine was determined using a 
Jaffé rate reaction measured with a CX3 ana-
lyzer (Beckman Instruments, Inc., Brea, CA) 
(NCHS 2007).
CRP is a marker of inflammation and 
has been associated with obesity (Dowd et al. 
2010). Serum CRP was measured by a high-
sensitivity assay using latex-enhanced neph-
elometry, with a lower limit of detection of 
the assay of 0.1 mg/L. CRP was categorized 
in weighted tertiles. Serum cotinine, a marker 
of exposure to environmental tobacco smoke, 
was categorized by weighted quartiles.
Statistical methods. We used sample 
weights for analyses to account for the com-
plex sampling design and nonresponse of 
NHANES; these were calculated according 
to NHANES guidelines (NCHS 2008c). We 
estimated sampling errors using the Taylor 
series linearized method. We used separate lin-
ear regression models to estimate associations 
between BMI z-scores and WC (as dependent 
variables) and individual or grouped PAHs 
categorized according to quartiles (based on 
the weighted distributions in the study popula-
tion). We used multinomial logistic regression 
models to simultaneously estimate adjusted 
odds ratios (ORs) for obesity and overweight 
status as distinct outcomes (compared with 
normal/underweight) in association with cate-
gorical PAH exposures. In addition to estimat-
ing associations for all observations combined, 
we performed separate analyses stratified by age 
(6–11 years and 12–19 years).
Table 1. Weighted characteristics of NHANES 2001–2006 participants 6–19 years of age.
Characteristic 6–19 years 6–11 years 12–19 years
n 3,189 1,081 2,108
1-naphthol (ng/L) 1604.55 (48.24) 1370.51 (59.58) 1804.98 (77.10)
2-naphthol (ng/L) 2530.30 (81.94) 2032.47 (74.13) 2979.43 (131.06)
2-fluorene (ng/L) 249.89 (7.25) 212.32 (6.92) 282.95 (10.35)
3-fluorene (ng/L) 105.58 (3.45) 89.35 (3.16) 119.97 (4.90)
1-phenanthrene (ng/L) 135.48 (3.75) 122.68 (3.82) 145.95 (4.90)
2-phenanthrene (ng/L) 50.10 (1.55) 42.74 (1.42) 56.49 (2.35)
3-phenanthrene (ng/L) 106.54 (3.46) 101.92 (4.00) 110.15 (4.17)
1-pyrene (ng/L) 98.91 (3.36) 95.58 (3.85) 101.49 (4.16)
∑PAHs (ng/L) 5704.66 (167.69) 4891.34 (189.24) 6417.88 (262.67)
Age (years) 11.81 (0.14) 8.37 (0.07) 15.23 (0.08)
BMI z-score 0.77 (0.02) 0.74 (0.04) 0.79 (0.03)
C-reactive protein (mg/dL) 0.05 (0.00) 0.04 (0.00) 0.05 (0.00)
Blood cotinine (ng/mL) 0.16 (0.02) 0.09 (0.01) 0.24 (0.03)
BMI 20.50 (0.13) 17.92 (0.14) 22.64 (0.16)
Urinary creatinine (mg/dL) 113.72 (2.46) 91.73 (2.07) 133.51 (3.11)
Sex
Male 51.34 ± 1.25 51.14 ± 2.13 51.49 ± 1.48
Female 48.66 ± 1.25 48.86 ± 2.13 48.51 ± 1.48
Race/ethnicity
Non-Hispanic white 62.18 ± 2.28 60.06 ± 2.71 64.74 ± 2.53
Non-Hispanic black 14.71 ± 1.48 15.00 ± 1.68 14.49 ± 1.52
Mexican American 11.79 ± 1.19 13.21 ± 1.30 10.75 ± 1.31
Other Hispanic 5.22 ± 0.81 4.59 ± 1.27 5.68 ± 0.97
Other 6.11 ± 0.75 7.14 ± 1.32 5.34 ± 0.82
Weight (n)
Obese 608 (15.53 ± 0.98) 204 (14.17 ± 1.44) 404 (16.54 ± 1.14)
Overweight 510 (16.69 ± 0.89) 169 (16.60 ± 1.43) 341 (16.76 ± 1.53)
Normal and underweight 2,071 (67.78 ± 1.23) 708 (69.23 ± 1.99) 1,363 (66.70 ± 1.66)
Poverty income ratio (PIR)
PIR ≤ 1 22.22 ± 1.43 22.55 ± 1.76 21.96 ± 1.87
PIR > 1 77.78 ± 1.43 77.45 ± 1.76 78.04 ± 1.87
TV and video games use
≤ 2 hr 48.61 ± 1.63 52.46 ± 2.38 45.70 ± 1.89
> 2 hr 51.39 ± 1.63 47.54 ± 2.38 54.30 ± 1.89
Caloric intake
Normal intake 53.95 ± 1.20 50.10 ± 1.91 56.78 ± 1.75
Excessive intake 46.05 ± 1.20 49.90 ± 1.91 43.22 ± 1.75
C-reactive protein
Tertile 1, ≤ 0.01 mg/dL 28.76 ± 1.07 34.68 ± 1.89 24.69 ± 1.56
Tertile 2, > 0.01–0.07 mg/dL 38.26 ± 1.10 35.91 ± 2.03 39.88 ± 1.39
Tertile 3, > 0.07 mg/dL 32.98 ± 1.00 29.41 ± 1.99 35.43 ± 1.53
Values are geometric mean (SE) or percent ± SE.
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SAS version 9.2 (SAS Institute Inc., 
Cary, NC) was used for all statistical analyses, 
and SAS-Callable SUDAAN 10 (Research 
Triangle Institute, Research Triangle Park, 
NC) was used to account for the NHANES 
complex sample design. p-Values from 
Satterthwaite statistics were presented at the 
significance level ≤ 0.05.
Results
Table 1 illustrates the weighted characteris-
tics and geometric mean concentrations (SE) 
of urinary PAH metabolites among par-
ticipants 6–19 years of age from NHANES 
2001–2006 included in this study (n = 3,189). 
The geometric mean age of the participants 
was 11.8 years and 51.3% were male. Non-
Hispanic whites accounted for 62.2% of the 
total study group; 14.7% were non-Hispanic 
blacks, and 11.8% were Mexican American. 
Approximately 22.2% of the participants were 
from families with income at or below the 
poverty level (PIR ≤ 1). The geometric mean 
(SE) BMI z-score was 0.77 (0.02); 15.5% of 
the individuals were classified as obese and 
16.7% as overweight. Approximately 14.2% 
of children 6–11 years of age were obese, 
whereas the percentage of obese individuals 
among adolescents (12–19 years) was 16.5%. 
Estimated mean values for BMI z-score and 
WC increased monotonically with increasing 
quartiles of ∑molPAHs in the population as 
a whole, and among children ages 6–11 years 
(Table 2). Positive associations were also 
estimated for the older age group, though 
adjusted mean values were similar for all 
exposure quartiles above the reference expo-
sure group, without a consistent increasing 
trend. BMI z-score and WC also increased 
monotonically with increasing quartiles of 
∑NAPHT among children 6–11 years of 
age, whereas associations in adolescents and 
the overall population were positive but not 
monotonic (Table 2).
ORs from adjusted multinomial logistic 
regression models indicated positive asso-
ciations with obesity for ∑molPAHs and 
∑NAPHT in the population as a whole and 
in both age groups, although monotonic 
increases with exposure were estimated for 
∑molPAHs in children 6–11 years of age 
only (Table 3). Neither exposure was associ-
ated with overweight in the population as a 
whole or in either age group.
Associations with individual PAH metab-
olites and with ∑mol3–4PAHs were less 
precise than those estimated for ∑molPAHs 
and ∑NAPHT, but 2-naphthol was posi-
tively associated with BMI z-score, WC, and 
obesity (overall and in both age groups), and 
1-phenanthrene and 2-phenanthrene were 
positively associated with BMI z-score and 
WC (overall and in both age groups) (see 
Supplemental Material, Tables S1 and S2).
Discussion
To our knowledge, this is the first report of 
an association of environmental PAH expo-
sures with childhood obesity using a nation-
ally representative sample.
In the present study, we found that 
∑NAPHT and ∑molPAHs were positively 
and significantly associated with BMI z-score, 
WC, and obesity. These associations were evi-
dent in the younger age group (6–11 years), 
but not in the older age group (12–19 years). 
It is worthwhile to note that the main source 
of exposure for naphthalene is through inha-
lation (mostly ambient pollution), whereas 
for the larger PAHs (fluorene, phenantrene, 
and pyrene), the main source of exposure is 
Table 2. Multivariate linear regression β coefficient (95% CI)a association between BMI z-score, waist 
circumference, and quartileb of ∑molPAHs, or ∑NAPHT.
Exposure
BMI z-score Waist circumference
β coefficient (95% CI) p-Value β coefficient (95% CI) p-Value
ALL (6–19 years) n = 3,189 n = 3,189
∑molPAHs Q1 Referent Referent
∑molPAHs Q2 0.18 (0.04, 0.32) 0.01 1.37 (–0.11, 2.85) 0.07
∑molPAHs Q3 0.18 (0.01, 0.35) 0.04 1.34 (–0.28, 2.96) 0.10
∑molPAHs Q4 0.25 (0.08, 0.43) 0.01 2.24 (0.25, 4.23) 0.03
∑NAPHT Q1 Referent Referent
∑NAPHT Q2 0.22 (0.06, 0.39) 0.01 1.79 (0.15, 3.43) 0.03
∑NAPHT Q3 0.24 (0.08, 0.40) < 0.01 1.78 (0.24, 3.32) 0.02
∑NAPHT Q4 0.31 (0.15,0.50) < 0.01 2.68 (0.88, 4.49) < 0.01
Children (6–11 years) n = 1,081 n = 1,081
∑molPAHs Q1 Referent Referent
∑molPAHs Q2 0.20 (–0.04, 0.44) 0.09 1.08 (–0.85, 3.00) 0.27
∑molPAHs Q3 0.24 (–0.02, 0.49) 0.07 1.36 (–0.83, 3.56) 0.22
∑molPAHs Q4 0.41 (0.04, 0.77) 0.03 3.30 (0.24, 6.35) 0.03
∑NAPHT Q1 Referent Referent
∑NAPHT Q2 0.25 (–0.03, 0.52) 0.07 1.56 (–0.68, 3.80) 0.17
∑NAPHT Q3 0.31 (0.04, 0.56) 0.02 1.95 (–0.44, 4.34) 0.11
∑NAPHT Q4 0.37 (0.03, 0.70) 0.03 3.07 (0.19, 5.96) 0.04
Adolescents (12–19 years) n = 2,108 n = 2,108
∑molPAHs Q1 Referent Referent
∑molPAHs Q2 0.20 (0.01, 0.39) 0.04 2.37 (–0.07, 4.82) 0.06
∑molPAHs Q3 0.12 (–0.14, 0.38) 0.35 2.01 (–1.16, 5.17) 0.21
∑molPAHs Q4 0.18 (–0.06, 0.43) 0.13 2.65 (–0.16, 5.45) 0.06
∑NAPHT Q1 Referent Referent
∑NAPHT Q2 0.24 (0.04, 0.45) 0.02 2.83 (0.35, 5.31) 0.03
∑NAPHT Q3 0.21 (–0.01, 0.45) 0.08 2.53 (–0.07, 5.12) 0.06
∑NAPHT Q4 0.32 (0.07, 0.59) 0.02 3.66 (1.15, 6.17) 0.01
aAdjusted for age, race/ethnicity, sex, urinary creatinine, PIR, serum cotinine, serum C-reactive protein, calorie intake, 
and television, video game, and computer usage. bQuartiles (Q) ∑molPAHs (nmol/L): Q1: ≤ 19.90; Q2: 19.91–34.89; 
Q3: 34.90–64.48; Q4: > 64.48. Quartiles ∑NAPHT (ng/L): Q1: ≤ 2404.34; Q2: 2404.35–4259.03; Q3: 4259.04–8256.64; 
Q4: > 8256.64. 
Table 3. OR (95% CI)a from multinomial logistic regression models of association between urinary quartileb PAHs and obesity and overweight versus normal/
underweight.
Exposure
6–19 years 6–11 years 12–19 years
Obese vs. normal Overweight vs. normal Obese vs. normal Overweight vs. normal Obese vs. normal Overweight vs. normal
∑molPAHs Q1 1.00 1.00 1.00 1.00 1.00 1.00
∑molPAHs Q2 2.08 (1.21, 3.56) 1.12 (0.75, 1.67) 1.99 (0.83, 4.75) 1.45 (0.73, 2.89) 2.37 (1.18, 4.77) 0.95 (0.58, 1.56)
∑molPAHs Q3 1.74 (1.00, 3.05) 0.96 (0.61, 1.52) 1.78 (0.81, 3.90) 1.30 (0.60, 2.81) 1.76 (0.71, 4.35) 0.70 (0.37, 1.33)
∑molPAHs Q4 2.56 (1.40, 4.69) 0.87 (0.53, 1.41) 4.42 (1.57, 12.42) 1.12 (0.43, 2.92) 2.16 (0.94, 4.98) 0.67 (0.33, 1.35)
∑NAPHT Q1 1.00 1.00 1.00 1.00 1.00 1.00
∑NAPHT Q2 1.99 (1.12, 3.53) 1.47 (0.94, 2.31) 1.52 (0.61, 3.79) 1.96 (0.96, 4.00) 2.58 (1.24, 5.40) 1.24 (0.72, 2.14)
∑NAPHT Q3 1.70 (1.02, 2.81) 1.00 (0.66, 1.50) 1.77 (0.77, 4.06) 1.27 (0.55, 2.90) 1.83 (0.79, 4.23) 0.80 (0.48, 1.35)
∑NAPHT Q4 2.53 (1.40, 4.56) 0.89 (0.59, 1.39) 3.24 (1.27, 8.28) 0.78 (0.28, 2.12) 2.54 (1.14, 5.68) 0.88 (0.47, 1.67)
aAdjusted for age, race/ethnicity, gender, urinary creatinine, poverty income ratio (PIR), serum cotinine, serum c-reactive protein, calorie intake, and television, videogame 
and computer usage. bQuartiles (Q) ∑molPAHs (nmol/L): Q1: ≤ 19.90; Q2: 19.91–34.89; Q3: 34.90–64.48; Q4: > 64.48. Quartiles ∑NAPHT (ng/L): Q1: ≤ 2404.34; Q2: 2404.35–4259.03; 
Q3: 4259.04–8256.64; Q4: > 8256.64.
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dietary (Li et al. 2008). Our results are in 
agreement with previous studies done both in 
animals and in humans. Irigaray et al. (2006) 
reported that PAH exposure impaired adipose 
tissue lipolysis and led to increased weight 
gain and fat mass in mice.
Recently, Rundle et al. (2012), in a longi-
tudinal birth cohort of African Americans 
and Dominican mothers (18–35 years of age) 
residing in New York City, investigated the 
effect of prenatal exposure to airborne PAHs 
on the child’s body size at 5 (n = 422) and 7 
(n = 341) years of age. The authors reported 
that exposure to ambient high-molecular-
weight PAHs was associated with higher BMI 
z-scores and obesity at both 5 and 7 years of 
age (Rundle et al. 2012).
PAHs are suspected endocrine-disrupt-
ing chemicals (EDCs) (Gozgit et al. 2004; 
Sievers et al. 2013). Using a Saccharomyces 
cerevisiae system, Schultz and Sinks (2002) 
reported estrogenic gene activity of the 
hydroxylated metabolites of naphthalene 
such as 1-naphthol and 2-naphthol, but not 
of the parent compound. Estrogenic activ-
ity was also reported for 2-fluorene and 
1-pyrene (Schultz and Sinks 2002). It has 
been proposed that exposure to EDCs and 
other chemicals is an important risk factor 
for childhood obesity (Grun and Blumberg 
2006). These chemicals can act on adipocytes 
by altering the metabolism or lipid homeo-
stasis through activation of the peroxisome 
proliferator–activated receptor (PPAR), 
which differentiates the pre-adipocyte cells 
in fat tissue (Grun and Blumberg 2006). 
Chemicals that have been reported to act 
through this mechanism in experimental 
models are organotins, such as tributyltin, 
perfluoroalkyl acids, and certain phthalates 
(Grun and Blumberg 2006). In an in vitro 
system, Kim et al. (2005) reported activation 
of both PPARα and PPARβ/δ after expo-
sure to several PAHs. Both naphthalene and 
phenanthrene significantly increased PPAR 
expression, though more weakly than benz[a]
anthracene. Experimental animal studies 
show that other EDCs such as bisphenol A 
(Rubin and Soto 2009) and polybrominated 
diphenyl ethers (Hoppe and Carey 2007) 
may promote adipogenesis through a second-
ary metabolic imbalance instead of through 
PPAR. Coplanar polychlorinated biphenyls, 
for example, increased adipo genesis through 
the binding of the aryl hydrocarbon receptor 
in adipocytes (Arsenescu et al. 2008).
Chang and Liao (1987) studied the 
effect of phenanthrene in castrated rats. They 
found that the compound bound weakly 
to the AR of rat prostate but did not bind 
to the estrogen receptor or the glucorticoid 
receptor. Higher activity was reported for 
the phenanthrene metabolite. Also, both 
phenanthrene and its metabolite reduced the 
androgen-dependent growth of the ventral 
prostate, seminal vescical, and coagulating 
gland (Chang and Liao 1987).
A slight antiandrogenic effect of phenan-
threne was similarly reported by Vinggaard 
et al. (2000) in an in vitro system. The 
authors also reported antiandrogenic effect of 
fluorantene (Vinggaard et al. 2000).
EDCs may also influence adipogenesis 
through effects on thyroid hormone. Thyroid 
hormone inhibits lipogenesis (Viguerie et al. 
2002) and stimulates lipolysis in adipocytes 
(Smith et al. 1991; Van Inwegen et al. 1975), 
possibly through crosstalk with the PPARs 
(reviewed in Lu and Cheng 2010). In animal 
models, thyroid hormone receptor (TR) ago-
nists induced fat loss and decreased plasma 
cholesterol and triglyceride levels (Baxter et al. 
2004; Grover et al. 2003). There is evidence 
that 1-naphthol and 2-naphthol act as EDCs 
through thyroid hormone receptor antagonist 
activity (Sun et al. 2008). Using an in vitro 
system based on the thyroid hormone recep-
tor (TR)-luciferase reporter gene, Sun et al. 
(2008) tested carbaryl, 1-naphthol, and 
2-naphthol for their TR activities. 1-naphthol, 
2-naphthol, and carbaryl showed TR antago-
nist activities, indicating that they could 
disrupt the normal function of the thyroid 
hormones. Whereas 2-naphthol is an impor-
tant metabolite of naphthalene, 1-naphthol is 
a metabolite of both carbaryl and naphthalene. 
Therefore, it may be possible that 1-naphthol 
and 2-naphthol may increase adipocyte lipid 
accumulation through TR antagonism and 
by reducing circulation levels of thyroid 
 hormones in children.
Li et al. (2008), using the NHANES 
2001–2002 survey, reported that the eight 
PAH metabolites correlate to each other to 
some degree (r = 0.4–0.8), which in some 
cases suggests a common source of exposure. 
Naphthalene metabolites, as a group, cor-
relate better with the fluorene group than 
with the phenanthrene and pyrene groups. 
This may be explained by the difference in 
exposure source: exposure through inhala-
tion for naphthalene, and by diet for the 
larger PAHs (fluorene, phenantrene, and 
pyrene). Although these metabolites have a 
good correlation with each other, our analy-
ses show a difference in association between 
individual PAH metabolites and obesity and 
body weight outcomes. Our finding may 
be explained, for example, by the different 
action on the estrogen-responsive genes by 
the different PAHs, as shown by Gozgit 
et al. (2004).
The temporal relations between exposures 
and outcomes cannot be determined given 
the cross-sectional study design. Although we 
controlled for several factors associated with 
obesity, exposure to other chemicals such 
as bisphenol A (Trasande et al. 2012) and 
phthalates (Teitelbaum et al. 2012; Trasande 
et al. 2013) might have confounded associa-
tions. Another important limitation is that 
PAHs have a short half-life, and exposure val-
ues are based on single spot urine analyses. 
Low-molecular-weight PAHs are ubiquitous 
in the environment, so it may be reasonable 
to assume that exposure is continuous. If so, 
urinary PAHs may be a good proxy for typi-
cal PAH exposures. Although no studies link 
short-term PAH exposure to long-term expo-
sure, there are examples of other lipophilic 
chemicals, such as phthalates, for which a 
single urine sample may represent exposure 
over the previous 3 months (Hauser et al. 
2004). We do not know whether this would 
apply to the PAHs, but our results merit 
 further investigation.
Conclusion
We found that the total molar sum of the 
PAHs was associated with higher BMI, WC, 
and obesity in children 6–11 years of age. 
However, this association was less consis-
tent among adolescents (12–19 years of age) 
in the same survey. We found that urinary 
naphthalene was associated with higher BMI 
z-score, WC, and obesity in both children 
and adolescents.
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